about
Perphenazine versus low-potency first-generation antipsychotic drugs for schizophreniaFlupenthixol versus low-potency first-generation antipsychotic drugs for schizophreniaFluphenazine versus low-potency first-generation antipsychotic drugs for schizophreniaHaloperidol versus low-potency first-generation antipsychotic drugs for schizophreniaTrifluoperazine versus low-potency first-generation antipsychotic drugs for schizophreniaFlupenthixol versus low-potency first generation antipsychotic drugs for schizophreniaFluphenazine versus low-potency first generation antipsychotic drugs for schizophreniaHaloperidol versus low-potency first-generation antipsychotic drugs for schizophreniaPerphenazine versus low-potency first generation antipsychotic drugs for schizophreniaTrifluoperazine versus low-potency first generation antipsychotic drugs for schizophreniaComparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisFlupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study.Neuropsychological performance in adult attention-deficit hyperactivity disorder: meta-analysis of empirical data.Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study.Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program.Analysis of polymorphisms in the olfactory G-protein Golf in major depression.Identification of a naturally occurring polymorphism in the promoter region of the norepinephrine transporter and analysis in major depression.Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.Cardiovascular adverse reactions during antidepressant treatment: a drug surveillance report of German-speaking countries between 1993 and 2010.Psychosocial and demographic factors associated with response to prophylactic lithium: a systematic review for bipolar disorders.Is the superior efficacy of new generation antipsychotics an artifact of LOCF?A Randomized Controlled Trial of Group Coping-Oriented Therapy vs Supportive Therapy in Schizophrenia: Results of a 2-Year Follow-up.Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale.Neurobiological underpinnings of shame and guilt: a pilot fMRI study.A case of persistent retrograde amnesia following a dissociative fugue: neuropsychological and neurofunctional underpinnings of loss of autobiographical memory and self-awareness.Use and safety of antiepileptic drugs in psychiatric inpatients-data from the AMSP study.Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis.Empirical correlates for the minnesota multiphasic personality inventory-2-restructured form in a german inpatient sample.Information processing during eye tracking as revealed by event-related potentials in schizophrenics, alcoholics, and healthy controls.Effect of aripiprazole on cognition in the treatment of patients with schizophrenia.Imputation of response rates from means and standard deviations in schizophrenia.Do patients with paranoid and disorganized schizophrenia respond differently to antipsychotic drugs?Seizures during antidepressant treatment in psychiatric inpatients--results from the transnational pharmacovigilance project "Arzneimittelsicherheit in der Psychiatrie" (AMSP) 1993-2008.Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.Tryptophan hydroxylase gene 1 polymorphisms are not associated with suicide attempts in alcohol-dependent individuals.Effects of scopolamine on matching to sample paradigm and related tests in human subjects.Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression.Clinical effects of COX-2 inhibitors on cognition in schizophrenia.Disentangling the adult attention-deficit hyperactivity disorder endophenotype: parametric measurement of attention.Equipercentile linking of scales measuring functioning and symptoms: examining the GAF, SOFAS, CGI-S, and PANSS.
P50
Q24193168-9F1B94C4-9065-4A30-9052-7250B7E6A90BQ24193881-855EFA64-BB60-48B3-A61D-292ADE0589C2Q24194501-FBA5DED3-B8DC-4BD9-A1EA-31F9BC097228Q24194891-D151350E-B65E-4CDD-AD1B-A0CCCC019438Q24194898-84DD2B83-802B-4588-9D78-18E77A2FB825Q24235116-2E14769F-88BE-43BC-8B7E-A2DF0FB4B6E5Q24235274-F28E6582-1AF7-43FB-B985-1C7A2B078CE6Q24235300-375C0F82-64D7-459B-948D-E282CE4A22B2Q24236586-1A2D2202-9FB7-427B-AFAF-E6838D01C49AQ24236681-7615281F-9310-499F-9AE5-9867F2FFEA82Q28293647-FB71F6D0-099F-461F-A967-D1CC7154DF28Q30654033-9D16347C-4A29-4D92-82A7-B03E73761B97Q30991969-9317826E-C765-4A29-9EB6-2EDDDBB87964Q33275210-8DB809A2-3E4A-4CA2-A77F-00589F7236F6Q33470766-AB50BB32-8708-49A4-B096-B6651448A2F2Q34119266-D729D96A-D368-4E56-A725-897154E2AA41Q34121502-EF639EE4-CA60-4263-8A98-130A34196BB9Q35165445-492414AC-2C8D-47B1-90FB-91087F1F5210Q35178973-CD7E378C-5D8E-44EA-AE01-9D311EE23823Q36318629-D53192C3-809F-4B0D-B21D-122529D13C81Q37076000-C615AAA3-C00C-4A2D-93C9-B600DE7E02DCQ37124959-AED58786-AEFD-4748-B768-9BDF4D46477DQ37384442-04C41D0A-2353-4874-85A4-95E72554AADDQ37535811-3A748FB7-FAB9-4D52-94D2-EEC2370C78FCQ38388708-85685C8A-105E-4F7E-B06F-84F35CD46A57Q38647529-A56580B1-AAEB-4B24-B0D6-086918B57D32Q38860420-1F74E778-AE3A-45E9-BA40-E17058C37378Q39029364-C1D04138-D83C-4544-8490-6327F20BA345Q41670671-F15F81F6-B071-408F-8E8F-A43FCB4C76EEQ43119233-52651684-EFB3-4CAA-AFF3-92039BC81E03Q43463249-6A07EE27-849E-4A85-B32D-CA5677C6B42CQ43789375-052664BD-8693-41E4-B7D7-7697F0539553Q43800445-85A5746F-2805-450E-8655-0AA42BC17E79Q43873912-2454C3BB-7FC9-4563-B914-5C431C9F6072Q44415919-3FF8D783-B3A9-4944-9EE1-CF9677F0601CQ44592908-8E95B144-D862-43A6-A510-3598D94F7CF6Q44752400-FBE1E96D-21A7-44C7-82BC-B18530E7247EQ45153924-57050147-4F4E-46A7-80EB-A5A057F5C37BQ45337217-F2E02251-078A-463B-99C4-9C27A6175A6CQ46547234-3C0F2D60-5C1E-4393-B363-4CFE92892856
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Rolf R. Engel
@ast
Rolf R. Engel
@en
Rolf R. Engel
@es
Rolf R. Engel
@nl
Rolf R. Engel
@sl
type
label
Rolf R. Engel
@ast
Rolf R. Engel
@en
Rolf R. Engel
@es
Rolf R. Engel
@nl
Rolf R. Engel
@sl
prefLabel
Rolf R. Engel
@ast
Rolf R. Engel
@en
Rolf R. Engel
@es
Rolf R. Engel
@nl
Rolf R. Engel
@sl
P1006
P214
P227
P244
P1006
P1153
7202511326
P21
P213
0000 0000 8385 225X
P214
P227
1037806948
P244
P31
P496
0000-0001-8022-3228
P569
1946-01-01T00:00:00Z
P735
P7859
lccn-n86032708